L-Glutamine (Gut Health) — Research Profile

Glutamine is the primary fuel for intestinal epithelial cells and supports tight junction proteins that seal the gut barrier. Clinical studies in surgical patients show it preserves intestinal permeability during stress. For "leaky gut" in functional GI conditions, 5-10g/day is commonly recommended by integrative practitioners, with supporting mechanistic evidence.

Most practitioners recommend a minimum of 4-8 weeks of consistent supplementation (5-10g/day) to see meaningful gut barrier improvements. Intestinal epithelial cells turn over every 3-5 days, so glutamine supports ongoing repair rather than providing a one-time fix. Some people notice digestive symptom improvement within 1-2 weeks.

Yes, for gut health purposes. Taking glutamine on an empty stomach ensures it reaches the intestinal epithelium without competing with other amino acids from food for absorption. Many practitioners recommend taking it first thing in the morning and before bed.

The controlled gut research used free L-glutamine powder at 5 g three times daily; no salt, buffered, or "gut-specific" formulation has been shown superior for intestinal outcomes. L-glutamine and glutamine are the same compound, so the real choice is powder versus capsules based on the gram amount you need to reach.

The strongest gut evidence is a single randomized trial in diarrhea-predominant IBS following an enteric infection, where 15 g/day for 8 weeks produced a 50-point-or-greater drop in IBS severity in 79.6% of patients versus 5.8% on placebo and normalized intestinal permeability. Mechanistic and review work shows glutamine fuels intestinal cells and supports tight-junction proteins such as occludin, ZO-1 and claudins, but broad "leaky gut" benefit outside this specific post-infectious population is not proven.

The only positive gut trial used 5 g three times daily, or 15 g/day total; no dose-ranging study has defined a minimum effective amount for intestinal symptoms. A risk assessment documents intakes up to 14 g/day as having the strongest safety record, so the trial dose sits just above that well-characterized level.

The post-infectious IBS trial split the dose into three servings across the day but never compared timing against meals or a specific time of day, so no optimal clock time has been established for gut effects. Dividing the daily total into several doses is simply the regimen the evidence used.

In the 8-week IBS trial, adverse events and study-drug discontinuations were low and similar to placebo, with no serious events reported. Reference monographs add that people sensitive to MSG (monosodium glutamate) may react because glutamine is converted to glutamate, and that high intakes are a problem in liver disease and can lower the seizure threshold in susceptible people.

Reference monographs flag three moderate interactions: glutamine may reduce the effectiveness of lactulose because it raises ammonia, may lower the effect of anti-seizure medications by acting on brain chemistry, and its use alongside chemotherapy is debated and should be oncologist-directed. These are theoretical or class-level cautions rather than effects measured in the gut trials.

The group with direct evidence is adults with diarrhea-predominant IBS and increased intestinal permeability following an enteric infection, who improved on 15 g/day over 8 weeks. Evidence does not support routine "gut repair" use in otherwise healthy people, and those with cirrhosis, hepatic encephalopathy, or a seizure disorder should avoid it.

The one controlled gut trial gave 5 g three times daily to adults with post-infectious diarrhea-predominant IBS and measured symptoms and intestinal permeability at an 8-week endpoint, so that is the timeframe with direct evidence. No study has mapped a week-by-week onset curve for gut symptoms, so a faster or slower response window has not been established.

A published risk assessment concluded the evidence for absence of adverse effects is strong up to 14 g/day, while noting data above that intake are insufficient to confirm long-term safety. The post-infectious IBS trial used 15 g/day for only 8 weeks with adverse-event rates similar to placebo, so daily use beyond roughly two months has not been directly studied for gut indications. People with cirrhosis or hepatic encephalopathy should avoid it because glutamine raises ammonia.

There is no formal tolerable upper limit; a risk assessment set an observed safe level of 14 g/day, above which the safety data become insufficient rather than showing clear harm. Reference monographs rate oral glutamine as possibly safe up to about 40 g/day short-term, but because the body converts it to ammonia, high intakes are unsafe for anyone with cirrhosis or hepatic encephalopathy.

No specific supplement stack has been tested for gut benefit; the post-infectious IBS trial used glutamine on its own. One practical caution: because glutamine is metabolized to ammonia, avoid pairing it with anything meant to lower ammonia, such as lactulose, where it may blunt the intended effect.

Glutamine is a single defined amino acid, so there is no active-fraction or extract standardization to verify; the meaningful checks are that it is plain L-glutamine and that it carries third-party purity and contaminant testing. Since the gut trial dosed 15 g/day split into three, a weighable powder makes hitting that gram target easier than counting many small capsules.